trial → CapableOf → combine pembrolizumab
Typicality: 0.339
Saliency: 0.209
Facets 3
with radiation therapy 4 other
with either idelalisib 3 other
at different doses 2 temporal
Open triples 3
trial → combine → pembrolizumab 5
trial → include → pembrolizumab 3
trial → compare → pembrolizumab 3
Sentiment analysis
negative neutral positive
0.075 0.723 0.202
Other statistics
Raw frequency 11
Normalized frequency 0.209
Modifier score 0.500
Perplexity 72.072